Sauchelli S, Rogers PJ, Fry G, Hamilton-Shield JP. Preference for high carbohydrate foods does not change for children and adolescents in insulin-induced hypoglycemia. BMJ Open Diabetes Res Care. 2022 Nov 8;10(6). doi: 10.1136/bmjdrc-2022-003065
Sauchelli S, Bradley J, England C, Searle A, Whitmarsh A. Exploring support needs of people living with diabetes during the coronavirus COVID-19 pandemic: insights from a UK survey. BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002162. doi: 10.1136/bmjdrc-2021-002162
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Schwab P, Saundankar V, Bouchard J, Wintfeld N, Suehs B, Moretz C, Allen E, DeLuzio A. Early treatment revisions by addition or switch for type 2 diabetes: impact on glycemic control, diabetic complications, and healthcare costs. BMJ Open Diabetes Res Care. 2016 Feb 18;4(1):e000099. doi: 10.1136/bmjdrc-2015-000099
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Anh DD, Baiqing D, Bhutta Z, Sur D, Whittington D. Cost of illness due to typhoid fever in five Asian countries. Trop Med Int Health. 2011 Mar 1;16(3):314-23.